Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial

Article Medicine, General & Internal

Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial

Scott A. Halperin et al.

Summary: The Ad5-nCoV vaccine showed a 57.5% efficacy against PCR-confirmed COVID-19 infection at least 28 days post-vaccination and demonstrated safety in healthy adults aged 18 years and older during the phase 3 trial.

LANCET (2022)

Add to Collection

Article Immunology

Safety and Immunogenicity of a Recombinant Adenovirus Type-5-Vectored Coronavirus Disease 2019 (COVID-19) Vaccine With a Homologous Prime-Boost Regimen in Healthy Participants Aged ≥6 Years: A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial

Fengcai Zhu et al.

Summary: The Ad5-vectored COVID-19 vaccine with a single dose was safe and well-tolerated in children and adolescents aged 6-17 years, and it induced robust immune responses. However, the boosting effect of the homologous prime-boost regime given 56 days apart was found to be limited.

CLINICAL INFECTIOUS DISEASES (2022)

Add to Collection

Letter Infectious Diseases

Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19

Wey Wen Lim et al.

LANCET MICROBE (2021)

Add to Collection

Editorial Material Biochemistry & Molecular Biology

Boosting immunity to COVID-19 vaccines

Jennifer A. Juno et al.

NATURE MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Denis Y. Logunov et al.

Summary: The Gam-COVID-Vac vaccine showed 91.6% efficacy against COVID-19 in the phase 3 trial, with good safety and tolerability in a large cohort of participants.

LANCET (2021)

Add to Collection

Article Immunology

Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates

Qian He et al.

Summary: Our study demonstrated that utilizing a heterologous prime-boost strategy with different combinations of COVID-19 vaccine candidates can enhance neutralizing antibody levels and T cell responses, providing new insights for vaccine development and application in controlling the SARS-CoV-2 pandemic.

EMERGING MICROBES & INFECTIONS (2021)

Add to Collection

Letter Medicine, General & Internal

WHO International Standard for anti-SARS-CoV-2 immunoglobulin

Paul A. Kristiansen et al.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data

Robert H Shaw et al.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial

Xinxue Liu et al.

Summary: Heterologous prime-boost COVID-19 vaccine schedules could facilitate mass immunisation, with ChAd/BNT showing non-inferior immunogenicity compared to ChAd/ChAd, but BNT/ChAd did not demonstrate non-inferiority to BNT/BNT. The results support flexibility in using heterologous prime-boost vaccination with ChAd and BNT COVID-19 vaccines.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey

Mine Durusu Tanriover et al.

Summary: The study presented the interim efficacy and safety results of the CoronaVac vaccine in a phase 3 clinical trial in Turkey, demonstrating high efficacy against PCR-confirmed symptomatic COVID-19 with good safety and tolerability profile. Results showed significant differences in the frequency of any adverse events between the vaccine and placebo groups, indicating excellent protective effects of the vaccine.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile

Alejandro Jara et al.

Summary: A study in Chile involving 10.2 million participants assessed the effectiveness of an inactivated SARS-CoV-2 vaccine developed in China. Fully immunized individuals had vaccine effectiveness of 65.9% for preventing Covid-19 and 87.5% for preventing hospitalization, 90.3% for preventing ICU admission, and 86.3% for preventing death.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Letter Medicine, General & Internal

Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination

Johan Normark et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Critical Care Medicine

BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers

Yaniv Lustig et al.

Summary: The study assessed early antibody responses after Pfizer-BioNTech BNT162b2 COVID-19 vaccine in Israeli healthcare workers. Results showed that 77% of participants had positive IgG response at week 3 after the first vaccine dose, with lower responses in older and immunosuppressed individuals. Timely second dose vaccinations are particularly important for these populations to enhance antibody responses and reduce breakthrough infections.

LANCET RESPIRATORY MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Estimating the early impact of vaccination against COVID-19 on deaths among elderly people in Brazil: Analyses of routinely-collected data on vaccine coverage and mortality

Cesar Victora et al.

Summary: The rapid scaling up of vaccination coverage among elderly individuals in Brazil was associated with significant declines in relative mortality compared to younger individuals, particularly in the context of the predominance of the gamma variant of the SARS-CoV-2 virus.

ECLINICALMEDICINE (2021)

Add to Collection

Letter Infectious Diseases